Biological and genetic landscape of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)

Eur J Surg Oncol. 2021 May;47(5):942-951. doi: 10.1016/j.ejso.2020.10.029. Epub 2020 Nov 2.

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of non-Hodgkin lymphoma (cancer of the immune system) that can develop around breast implants. Breast implants are among the most commonly used medical devices for cosmetic or reconstructive purposes. In the past few years, the number of women with breast implants diagnosed with anaplastic large cell lymphoma (ALCL) has increased, and several studies have suggested a direct association between breast implants and an increased risk of this disease. Although it has been hypothesized that chronic stimulation of the immune system caused by implant materials and biofilms as well as a possible genetic predisposition play an important role in this disease, the cellular and molecular causes of BIA-ALCL are not fully understood. This review aims to describe the current understanding around the environmental and molecular drivers of BIA-ALCL as well as the genetic and chromosomal abnormalities identified in this disease to date.

Keywords: Anaplastic large cell lymphoma; Bacterial biofilm; Breast implants; Chromosomal alterations; Genetic alterations; Immune system.

Publication types

  • Review

MeSH terms

  • Breast Implants / adverse effects*
  • Chromosome Aberrations
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Genes, p53
  • Humans
  • Janus Kinases / physiology
  • Lymphoma, Large-Cell, Anaplastic / etiology*
  • Lymphoma, Large-Cell, Anaplastic / genetics
  • Lymphoma, Large-Cell, Anaplastic / physiopathology
  • STAT3 Transcription Factor / physiology

Substances

  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Janus Kinases